GLP-1 drugs linked to better pregnancy rates in PCOS women and reduced cancer risk in diabetes patients

Key Findings

🛡️ GLP-1 drugs linked to 36% lower multiple myeloma risk

• Among 219,283 people with type 2 diabetes, GLP-1 receptor agonist users had a 36% lower risk of developing multiple myeloma compared to those not using these drugs

• The protective effect remained strong even in subgroups with BMI over 30 and poorly controlled diabetes (HbA1c over 8%)

• No significant associations were found with other blood cancers like chronic myeloid leukemia, acute myeloid leukemia, or myelodysplastic syndrome

🧠 Semaglutide changes food cravings in Japanese diabetes patients

• 20 Japanese adults with type 2 diabetes and visceral fat showed significant decreases in preferences for sweet and non-sweet carbohydrates and high-fat foods after semaglutide treatment

• Participants specifically reduced cravings for Japanese staple foods like white rice and udon/soba noodles, plus high-fat snacks

• The control group (12 people not receiving GLP-1 therapy) showed no changes in food preferences for any nutrient categories

⚠️ High-dose canagliflozin linked to 3x higher intestinal blockage risk

• Analysis of 192,359 participants across 50 studies found high-dose canagliflozin (300 mg/day) was associated with 3.4 times higher risk of intestinal obstruction

• This translates to about 1 extra case per 658 people treated—a small absolute risk but clinically meaningful

• Surprisingly, liraglutide was associated with 56% lower risk of intestinal obstruction, suggesting a protective effect

💔 GLP-1 drugs protect against heart failure through weight loss, not blood sugar

• Genetic analysis of 1.67 million participants found GLP-1 receptor activation reduced heart failure risk by about 50%

• The protection was primarily mediated by BMI reduction (67.2% of the effect) rather than glucose control (45%)

• Even after accounting for weight loss and diabetes status, residual protective effects remained, suggesting direct heart benefits

🦵 GLP-1 drugs cut amputation risk by 14% in high-risk diabetes patients

• Among 17,288 diabetes patients with prior major limb events, those starting GLP-1 drugs had 10% lower risk of recurrent limb problems and 14% lower amputation risk compared to DPP-4 inhibitor users

• The same patients also saw 38% lower risk of major cardiovascular events, 43% lower cardiovascular death risk, and 37% lower all-cause mortality

• Benefits extended to 39% lower risk of progressing to long-term dialysis

🍽️ People buy 7% less food after starting GLP-1 drugs

• Analysis of consumer food purchases showed people reduced their food spending after starting GLP-1 receptor agonists

• The reduction was consistent across different food categories, suggesting broad appetite suppression rather than selective food avoidance

• Purchase patterns aligned with the known appetite-suppressing effects of these medications in clinical trials